Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery

Chinese Journal of Cancer

Volumn 32, Issue 7, 2013, Pages 403-409

  Li, Bao Zhong ^a   Chen, Zhao Li ^a   Shi, Su Sheng ^b   Feng, Xiao Li ^b   Tan, Xiao Gang ^a   Zhou, Fang ^a   He, Jie ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Cdc25C; Esophageal squamous cell carcinoma; Radiation response; Survival

Indexed keywords

CHECKPOINT KINASE 2; CYCLIN D1; PROTEIN TYROSINE PHOSPHATASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PROTEIN EXPRESSION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CDC25 PHOSPHATASES; CHECKPOINT KINASE 2; COMBINED MODALITY THERAPY; CYCLIN D1; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PARTICLE ACCELERATORS; PROPORTIONAL HAZARDS MODELS; SMOKING; SURVIVAL RATE;

EID: 84879825782     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10233     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006,56:106-130.
2. Pera M, Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol, 2001,10:81-90.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med, 2003,349:2241-2252.
4. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol, 2003,4:481-488.
5. Katlic MR, Wilkins EW Jr, Grillo HC. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg, 1990,99:929-938.
6. Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis, 2002,23:1695-1700.
7. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol, 2006,24:748-754.
8. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res, 2007,13:1955-1960.
9. DiPaola RS. To arrest or not to G(2)-M cell-cycle arrest. Clin Cancer Res, 2002,8:3311-3314.
10. Fujita H, Kakegawa T, Kawahara H, et al. Preoperative radiation for carcinoma of the thoracic esophagus involving adjacent organs- a comparative and multivariate analysis of prognosis. Kurume Med J, 1992,39:175-181.
11. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys, 1998,41:579-583.
12. Doherty SC, McKeown SR, McKelvey-Martin V, et al. Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst, 2003,95:1859-1868.
13. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature, 2000,408:433-438.
14. 2 arrest through ERK mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation. Cell Cycle, 2006,5:759-765.
15. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther, 2002,1: 226-231.
16. Shinozaki H, Ozawa S, Ando N, et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res, 1996,2:1155-1161.
17. Inomata M, Uchino S, Tanimura H, et al. Amplification and overexpression of cyclin D1 in aggressive human esophageal cancer. Oncol Rep, 1998,5:171-176.
18. Itami A, Shimada Y, Watanabe G, et al. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology, 1999,57:311-317.
19. Ho-Pun-Cheung A, Assenat E, Thezenas S, et al. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int J Radiat Oncol Biol Phys, 2007,68:1094-1101.
20. Samejima R, Kitajima Y, Yunotani S, et al. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res, 1999,19:5515-5521.
21. Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer, 2005,104:2365-2372.
22. Prevost GP, Brezak MC, Goubin F, et al. Inhibitors of the CDC25 phosphatases. Prog Cell Cycle Res, 2003,5:225-234.
23. Broggini M, Buraggi G, Brenna A, et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res, 2000,20:4835-4840.
24. Nishioka K, Doki Y, Shiozaki H, et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer, 2001,85:412-421.
25. 2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer, 2007,7:861-869.